Medtronic Infuse Studies Faulted for Downplaying Side Effects

Medtronic Infuse Studies Faulted for Downplaying Side Effects

Medtronic Infuse Studies Faulted for Downplaying Side Effects

Medtronic Inc.’s published studies for its Infuse bone graft product may have downplayed serious side effects, according to an analysis published last year in The Spine Journal. The study, which drew on U.S. Food & Drug Administration (FDA) documents and other data sources, suggests that up to half of patients receiving Infuse may experience adverse events, including:

© 2005-2017 Parker Waichman LLP ®. All Rights Reserved.